景峰医药(000908) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥100,575,702.29, a decrease of 42.87% compared to ¥176,056,130.03 in the same period last year[3] - Net profit attributable to shareholders was ¥3,505,293.50, representing a significant increase of 174.14% from ¥1,278,629.96 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥1,848,275.03, up 191.11% from ¥634,895.22 in the previous year[3] - The net profit for Q1 2024 is CNY 4,999,711.10, a decrease of 42.5% compared to CNY 8,743,250.95 in Q1 2023[15] - The total comprehensive income for Q1 2024 is CNY 5,033,635.69, a decrease of 38.5% compared to CNY 8,142,115.82 in Q1 2023[15] Cash Flow and Assets - The net cash flow from operating activities decreased by 36.55% to ¥8,644,488.81 from ¥13,623,933.97 in the same period last year[3] - Cash and cash equivalents increased to CNY 14,923,877.12 from CNY 13,165,034.76 at the beginning of the period[12] - The cash flow from operating activities shows a net increase of CNY 8,644,488.81, compared to CNY 13,623,933.97 in the same period last year, reflecting a decline of 36.5%[16] - The cash flow from investing activities shows a net outflow of CNY 415,900.00, an improvement from a net outflow of CNY 5,259,594.09 in Q1 2023[16] Expenses and Liabilities - Total operating costs for Q1 2024 were CNY 103,667,185.25, down 38.6% from CNY 168,775,870.62 in the previous year[14] - The company experienced a 62.15% decrease in R&D expenses, attributed to lower investment compared to the same period last year[6] - The company incurred operating expenses of CNY 139,084,711.87, which is a reduction from CNY 194,283,595.58 in the previous year[16] - Total liabilities rose to CNY 1,248,555,275.02, compared to CNY 1,214,026,778.21 at the start of the quarter[12] Assets and Equity - Total assets at the end of the reporting period were ¥1,099,908,516.64, reflecting a growth of 3.73% from ¥1,060,346,384.15 at the end of the previous year[3] - The company's equity attributable to shareholders improved to -¥45,971,788.89, a 7.12% increase from -¥49,494,383.93 at the end of the previous year[3] - Accounts receivable increased to CNY 92,055,291.34, up from CNY 77,481,859.65 at the start of the quarter[12] - Inventory decreased slightly to CNY 63,623,193.84 from CNY 64,577,591.95 at the beginning of the period[12] - Deferred tax assets increased to CNY 12,552,242.04 from CNY 10,409,234.18 at the beginning of the period[12] Other Income and Government Subsidies - The company received government subsidies amounting to ¥2,651,768.60, contributing to a 363.96% increase in other income[6] - The company reported a 252.62% increase in prepayments, primarily due to increased procurement during the period[6] Earnings Per Share - Basic and diluted earnings per share increased to ¥0.0040, a rise of 166.67% from ¥0.0015 in the previous year[3] - The company reported a basic and diluted earnings per share of CNY 0.0040, up from CNY 0.0015 in Q1 2023, indicating a significant improvement[15] Additional Notes - The company has not reported any new product launches or significant market expansions during this quarter[18] - The financial report for Q1 2024 has not been audited[18]